<?xml version="1.0" encoding="UTF-8"?>
<GaPExchange xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:noNamespaceSchemaLocation="dbGaPEx2.1.5.xsd">

<MetaVariables>
	<Submitter/>
	<Method/>
</MetaVariables>
<MetaLinks/>

<Projects>
	<Project/>
	<Project/>
	<Project/>
</Projects>

<Studies>

<Study source="dbGaP" accession="phs000260.v2.p1" parentStudy="phs000260.v2.p1" createDate="2011-01-14" modDate="2011-05-04">

<Configuration>
	<Data_Provider><![CDATA[
		<table border="1">
		<tr><th>Title</th><th>Name</th><th>Institute</th></tr>
		<tr><td>Co-Principal Investigators</td><td>Zhiheng Pei, MD, PhD</td><td>NYU Langone Medical Center, New York, NY, USA</td></tr>
		<tr><td>Co-Principal Investigators</td><td>Karen Nelson, PhD</td><td>J Craig Venter Institute, Maryland, USA</td></tr>
		<tr><td>Co-Investigators</td><td>Liying Yang, MD, MS</td><td>NYU Langone Medical Center, New York, NY, USA</td></tr>
		<tr><td>Co-Investigators</td><td>Stuart Brown, PhD</td><td>NYU Langone Medical Center, New York, NY, USA</td></tr>
		<tr><td>Co-Investigators</td><td>Gary Andersen, PhD</td><td>Lawrence Berkeley National Lab, California, USA</td></tr>
		</table>
	]]></Data_Provider>
	<StudyNameEntrez>Foregut Microbiome in Development of Esophageal Adenocarcinoma</StudyNameEntrez>
	<StudyNameReportPage>Foregut Microbiome in Development of Esophageal Adenocarcinoma</StudyNameReportPage>
	<StudyTypes>
		<StudyType>Case-Control</StudyType>
	</StudyTypes>
	<Description><![CDATA[
<p>The distal esophagus is an important anatomical area where gastric acid reflux can cause reflux esophagitis (RE), 	Barrett&#39;s esophagus (BE) (intestinal metaplasia), and esophageal adenocarcinoma (EA). The incidence of EA has 	increased 6-fold in the U.S. since the 1970s, parallel to a significant increase in the prevalence of gastroesophageal 	reflux diseases (GERD). Although specific host factors might predispose one to disease risk, such a rapid increase in 	incidence must be predominantly environmental. The cause remains unknown. Our hypothesis is that changes in the 	foregut microbiome are associated with EA and its precursors, RE and BE in the GERD sequence.</p> 	<p>We will conduct a case control study to demonstrate the microbiome-disease association in every stage of GERD 	sequence as well as analyze the trend in changes in the microbiome along disease progression toward EA.</p> 	<p>Specific Aim 1. To conduct a comprehensive population survey of the foregut microbiome and demonstrate its 	association with GERD sequence, by 16S rRNA gene survey. We will analyze samples of the foregut microbiome at 	three anatomic loci: mouth, distal esophagus, and gastric corpus. Changes of the microbiota in the distal 	esophagus will be correlated with the phenotypes. Spatial relationship between the esophageal microbiota and 	upstream (mouth) and downstream (stomach) foregut microbiotas as well as temporal stability of the 	microbiome-disease association will also be examined.</p> 	<p>Specific Aim 2. To define distal esophageal metagenome and demonstrate its association with GERD sequence, 	by shotgun metagenomic analysis. We will first classify samples of the metagenome into metagenotypes by 	between-sample k-mer distance and correlate the metagenotypes with the four phenotypes. Subsequent detailed analyses 	will include pathway-disease and gene-disease associations. DNA viruses and fungi, if identified, also will be 	correlated with the phenotypes.</p> 	<p>A significant association between the foregut microbiome and GERD sequence, if demonstrated, will be the 	first step for eventually testing the causal hypothesis that an abnormal microbiome is required for the development 	of the sequence of phenotypic changes toward EA.</p> 	<p>If EA and its precursors represent a microbial ecological disease, treating the cause of GERD might become 	possible, for example, by normalizing the microbiome through use of antibiotics, probiotics, or prebiotics. 	Causative therapy for GERD could prevent its progression and reverse the current trend of increasing incidence 	of EA.</p>]]>
	</Description>
	<StudyInEx><![CDATA[
<p><b>Inclusion Criteria:</b><br/> 	Subjects will be screened by endoscopic examination, histological examination, and 48-hour pH monitoring.  A subject 	will be considered for enrollment into this study if the results of his/her screening examinations are diagnostic 	for one of the following four phenotypes: 	</p> 	<p> 		<ol> 			<li><i>Healthy control:</i> Healthy control will be selected from subjects who present to the GI Clinics with 			symptoms requiring upper GI endoscopic examination and/or other diagnostic tests.  The healthy control 			should meet all of one of the following sets of criteria: 1) normal endoscopic findings, 2) normal pH 			range with 48-hour pH monitoring study, and 3) no reflux symptoms, such as heart burn; <b><i>OR</i></b> 1) histopathological 			examination shows no inflammatory infiltrate or only less than 10 lymphocytes per high power field 			(HPF, 400x magnification) in the squamous epithelium, 2) normal pH range with 48-hour pH monitoring study, 			and 3) no reflux symptoms, such as heart burn.</li> 			<li><i>Reflux esophagitis (RE):</i> Esophagitis will be determined either: histologically, characterized by 			basal zone hyperplasia exceeding 20% of the epithelial thickness, papillae extending into the superficial 			third of the epithelium, and presence of lymphocytes equal to or more than 10 cells/HPF or any numbers of 			eosinophils or polymorphonuclear leukocytes <b><i>OR</i></b> based on endoscopic findings consistent with reflux esophagitis. 			Symptoms of reflux will also be inquired about at each patient visit, and reflux will be detected by 			using 48-h pH monitoring.</li> 			<li><i>Barrett&#39;s esophagus (BE):</i> esophageal squamous epithelium replaced by intestinal-type epithelial 			cells and goblet cells.</li> 			<li><i>Esophageal Adenocarcinoma (EA):</i> atypical, infiltrative intestinal-type glands associated with 			desmoplasia.  This phenotype also includes high grade dysplasia (carcinoma in situ).</li> 		</ol> 	</p> 	<p>The final decision on enrollment of a subject will be determined by frequency-match on gender, ethnic background, 	and age within 10 years.</p> 	<p><b>Exclusion Criteria:</b><br/> 		<ol> 			<li>Use of antibioics within 2 weeks before the scheduled endoscopic examination</li> 			<li>Previous gastric/esophageal surgery</li> 			<li>Active infection of the oral cavity</li> 			<li>Active gastric ulcer disease, or gastric cancer</li> 			<li>Persons younger than 50 years of age, because GERD and its complications are mainly diseases 			of older populations</li> 			<li>Pregnant women, because the natural history of reflux disease in pregnancy is different from GERD 			in general populations that leads to metaplasia and/or dysplasia</li> 			<li>Persons with an HIV infection will be excluded</li> 			<li>For safety reasons, we wll exclude potential subjects with coagulopathy (INR &gt; 2.0) or thrombocytopenia 			(platelet count &lt; 50) since this study involves repeated mucosal sampling.</li> 			<li>We will also exclude potential subjects at high risk for developing endocarditis, such as those 			with a history of endocarditis, rheumatic heart disease, or heart valve prosthesis who might require 			antibiotic prophylaxis for the endoscopic examination. </li> 			<li>We will exclude potential subjects with a history of intestinal ischemia and those with severe 			cardiopulmonary disease, or neurological impairment.</li> 			<li>We will exclude any subject who has an imperforate anus, recent anal or rectal surgery.</li> 			<li>English speakers will be excluded. Our project addresses the increasing incidence of esophageal 			adenocarcinoma in the US which has increased &gt; 6-fold since the 1970s, but in other parts of the world 			except Western Europe the trend is stable. Since non-English speakers most likely represent immigrants 			from foreign countries, their relationship with the increasing incidence of esophageal adenocarcinoma 			can not be easily defined.  Including non-English speakers could introduce unknown factors that may 			contribute to the change in the foregut microbiome and decrease the power of this demonstration 			project.</li> 		</ol> 	</p>]]>
	</StudyInEx>
	<StudyProjects>
		<Project/>
	</StudyProjects>
	<Publications>
		<Publication>
			<Pubmed pmid="15657344"/>
		</Publication>
		<Publication>
			<Pubmed pmid="17142109"/>
		</Publication>
		<Publication>
			<Pubmed pmid="15545159"/>
		</Publication>
		<Publication>
			<Pubmed pmid="9827707"/>
		</Publication>
		<Publication>
			<Pubmed pmid="16221805"/>
		</Publication>
		<Publication>
			<Pubmed pmid="17106919"/>
		</Publication>
		<Publication>
			<Pubmed pmid="11352068"/>
		</Publication>
		<Publication>
			<Pubmed pmid="16112578"/>
		</Publication>
		<Publication>
			<Pubmed pmid="16497592"/>
		</Publication>
		<Publication>
			<Pubmed pmid="17183312"/>
		</Publication>
		<Publication>
			<Pubmed pmid="11123195"/>
		</Publication>
		<Publication>
			<Pubmed pmid="11959090"/>
		</Publication>
		<Publication>
			<Pubmed pmid="16437628"/>
		</Publication>
		<Publication>
			<Pubmed pmid="15016918"/>
		</Publication>
		<Publication>
			<Pubmed pmid="2161310"/>
		</Publication>
		<Publication>
			<Pubmed pmid="10364004"/>
		</Publication>
		<Publication>
			<Pubmed pmid="1699893"/>
		</Publication>
		<Publication>
			<Pubmed pmid="12916665"/>
		</Publication>
		<Publication>
			<Journal authors="Glickman JN and Odze RD" title="Epithelial neoplasms of the esophagus" journal="Surgical Pathology of the GI tract, Liver, Biliary tract, and Pancreas	Odze RD, Goldblum JR, and Crawford JM.  Philadelphia: Saunders, 2004."/>
		</Publication>
		<Publication>
			<Pubmed pmid="1882791"/>
		</Publication>
		<Publication>
			<Pubmed pmid="19394334"/>
		</Publication>
		<Publication>
			<Pubmed pmid="19563840"/>
		</Publication>
		<Publication>
			<Journal authors="Tack J and Carethers JM" title="Different Microbiome Patterns in Normal, Inflammed, and Barrett&#39;s Esophagus" journal="Gastroenterology. 2009;137:398-399"/>
		</Publication>
		<Publication>
			<Pubmed pmid="19415112"/>
		</Publication>
		<Publication>
			<Pubmed pmid="19914921"/>
		</Publication>
		<Publication>
			<Pubmed pmid="20418441"/>
		</Publication>
		<Publication>
			<Pubmed pmid="20806429"/>
		</Publication>
	</Publications>
	<Diseases>
		<Disease vocab_source="MESH" vocab_term="Esophageal Adenocarcinoma"/>
		<Disease vocab_source="MESH" vocab_term="Barrett&#39;s Esophagus"/>
		<Disease vocab_source="MESH" vocab_term="GERD"/>
	</Diseases>
	<Attributions>
		<Header title="Co-Principal Investigators">
			<AttName>Zhiheng Pei, MD, PhD</AttName>
			<Institution>NYU Langone Medical Center, New York, NY, USA</Institution>
		</Header>
		<Header title="Co-Principal Investigators">
			<AttName>Karen Nelson, PhD</AttName>
			<Institution>J Craig Venter Institute, Maryland, USA</Institution>
		</Header>
		<Header title="Co-Investigators">
			<AttName>Liying Yang, MD, MS</AttName>
			<Institution>NYU Langone Medical Center, New York, NY, USA</Institution>
		</Header>
		<Header title="Co-Investigators">
			<AttName>Stuart Brown, PhD</AttName>
			<Institution>NYU Langone Medical Center, New York, NY, USA</Institution>
		</Header>
		<Header title="Co-Investigators">
			<AttName>Gary Andersen, PhD</AttName>
			<Institution>Lawrence Berkeley National Lab, California, USA</Institution>
		</Header>
		<Header title="Co-Investigators">
			<AttName>Eion Brodie, PhD</AttName>
			<Institution>Lawrence Berkeley National Lab, California, USA</Institution>
		</Header>
		<Header title="Co-Investigators">
			<AttName>Page Caufield, DDS, PhD</AttName>
			<Institution>NYU Langone Medical Center, New York, NY, USA</Institution>
		</Header>
		<Header title="Co-Investigators">
			<AttName>Yu Chen, PhD</AttName>
			<Institution>NYU Langone Medical Center, New York, NY, USA</Institution>
		</Header>
		<Header title="Co-Investigators">
			<AttName>Todd Desantis, MS</AttName>
			<Institution>Lawrence Berkeley National Lab, California, USA</Institution>
		</Header>
		<Header title="Co-Investigators">
			<AttName>Fritz Francois, MD</AttName>
			<Institution>NYU Langone Medical Center, New York, NY, USA</Institution>
		</Header>
		<Header title="Co-Investigators">
			<AttName>Xiaoyu Li, MD</AttName>
			<Institution>University of Florida - Jacksonville, Florida, USA</Institution>
		</Header>
		<Header title="Co-Investigators">
			<AttName>Mengling Liu, PhD</AttName>
			<Institution>NYU Langone Medical Center, New York, NY, USA</Institution>
		</Header>
		<Header title="Co-Investigators">
			<AttName>Michael Poles, MD, PhD</AttName>
			<Institution>NYU Langone Medical Center, New York, NY, USA</Institution>
		</Header>
		<Header title="Co-Investigators">
			<AttName>Morris Traube, MD</AttName>
			<Institution>NYU Langone Medical Center, New York, NY, USA</Institution>
		</Header>
		<Header title="Co-Investigators">
			<AttName>Patrick Yachimski, MD, MPH</AttName>
			<Institution>Vanderbilt University Medical Center, Tennessee, USA</Institution>
		</Header>
		<Header title="Co-Investigators">
			<AttName>Weimin Ye, MD, PhD</AttName>
			<Institution>Karolinska Instituet, Sweden</Institution>
		</Header>
		<Header title="Co-Investigators">
			<AttName>Shibu Yooseph, PhD</AttName>
			<Institution>J Craig Venter Institute, Maryland, USA</Institution>
		</Header>
		<Header title="Co-Investigators">
			<AttName>Steven Moss, MD</AttName>
			<Institution>Brown University/Rhode Island Hospital, Rhode Island, USA</Institution>
		</Header>
		<Header title="Co-Investigators">
			<AttName>Sharmila Anandasabapathy, MD</AttName>
			<Institution>Mount Sinai Medical Center, New York, USA</Institution>
		</Header>
	</Attributions>
	<DisplayPublicSummary>yes</DisplayPublicSummary>
	<StudyURLs>
		<Url name="Foregut Microbiome in the Development of Esophageal Adenocarcinoma" url="http://gerd.med.nyu.edu/"/>
	</StudyURLs>
	<StudyHistory><![CDATA[
<p>Gastroesophageal reflux disorders (GERD) refer to a sequence of diseases arising from gastric reflux, including 	reflux esophagitis (RE), Barrett&#39;s esophagus (intestinal metaplasia) (BE), and its downstream sequelum esophageal 	adenocarcinoma (EA).  The incidence of EA has increased &gt; 6-fold in the U.S. since the 1970s (1), parallel to 	an increasing prevalence of RE (2).  Despite numerous studies, no explanation has been found for the increase. 	Although prevalence of RE is increasing in both men and women, strong gender disparity with male predominance 	is obvious at the stages of BE and EA for reasons unknown (3-5).  The current strategy for dealing with the 	continuum of progression of GERD-related problems is limited to passive observation and symptomatic treatment, 	such as using proton pump inhibitors, and has been ineffective in preventing the increase in the incidence of EA. 	GERD, similar to other chronic diseases, likely has a multi-factorial etiology.  Although host factors likely 	play a role, such a rapid increase in incidence must be predominantly environmental.  Conventional studies 	have identified numerous risk factors, but their association with GERD is moderate (Table 1). The main 	factor(s) remain to be identified. The role of the microbiome in the development of inflammation-related 	cancers has been suggested by recent studies in some mouse models that mimic inflammatory bowel diseases (6). 	The development of mucosal inflammation and adenocarcinoma requires both a trigger (chemical or genetic) 	and the presence of commensal bacteria.  Although human exposure to several exogenous pathogens has been 	monitored, there has been little attention paid to changes in the indigenous microbiome.  This is partly 	due to the complexity and difficulties in culture and analysis of the human microbiome.</p> 	<p>Among the environmental agents that have been considered are microbes.  The human body can be viewed 	as a superorganism composed of an amalgam of both microbial and Homo sapiens cells.  Our relationship 	with bacteria can be considered to span a broad spectrum, from mutualism to pathogenicity (7).  There 	are currently two theories to explain bacterial diseases.  The classic pathogen theory, largely 	attributed to Koch, requires the presence of specific pathogens, such as Mycobacterium tuberculosis 	or Bacillus anthracis (8).  Alternatively, the microecological disease or "pathogenic microbial community" 	theory is a new concept in which the entire community contributes to pathogenicity although no individual 	community members can be categorized as classic pathogens (9).</p> 	<p>Non-pathogenic bacteria do not have classically defined virulence factors but may harm the host by their 	basic metabolic activities or structural components.  The gut microbiota in ob/ob mice, for example, has 	an increased capacity to harvest energy from the diet and might play a role in the pathophysiology of 	obesity (10).  Also, a structural component of the gram-negative outer membrane from non-pathogenic bacteria, 	lipopolysaccharide (LPS), can induce abnormal relaxation of the lower esophageal sphincter via activation of 	the iNOS pathway (11) and (12) delay gastric emptying through the COX-2 pathway. Both effects increase the 	chance of reflux.</p> 	<p>We have endeavored to understand the bacterial-host relationship in GERD in a stepwise way.  First, 	we performed a comprehensive study of the microbiota in the distal esophagus and demonstrated its complexity, 	despite little prior knowledge (13-14).  Surprisingly, the esophageal microbiota is comparable in complexity 	to those found in the mouth, stomach, colon, vagina, and skin.  Collectively, nine phyla were observed, 	represented by 166 species. The distal esophagus could harbor &gt; 200species, as predicted by the Chao-1 	richness estimator.   Second, we have demonstrated that in a high-risk population (elderly males) the 	esophageal microbiota can be classified into two types with the use of both unsupervised and phenotype-directed 	analyses, and that the type II biota is the strongest (OR &gt;15) amongst all known environmental factors that are 	associated with the pathological changes related to RE and BE.</p>]]>
	</StudyHistory>
	<ConsentGroups>
		<ConsentGroup groupNum="1" shortName="HMP" longName="Human Microbiome Research"/>
	</ConsentGroups>
</Configuration>

  <AuthorizedAccess>
    <DacInfo ssDacId="0">
      <DacName>eNCI DAC</DacName>
      <DacFullName>Extramural NCI Data Access Committee</DacFullName>
      <DacEmail>ncidac@mail.nih.gov</DacEmail>
      <DacPhone></DacPhone>
      <DacFax>301-435-5477</DacFax>
      <DacUrl>http://grants.nih.gov/grants/gwas</DacUrl>
    </DacInfo>
    <Policy Policy_ID="phs000260.v2.p1_policy" ref_ssDacId="0">
      <DisplayResearchStatement>yes</DisplayResearchStatement>
      <DisplayPublicSummary>yes</DisplayPublicSummary>
      <EmbargoLength>12</EmbargoLength>
      <YearsUntilRenewal>1</YearsUntilRenewal>
      <WeeksCancelRequest>8</WeeksCancelRequest>
      <PdfSupplementReqired>no</PdfSupplementReqired>
      <AcknowledgementText>
        <para>
               http://dbgap.ncbi.nlm.nih.gov/aa/wga.cgi?page=DUC&amp;view_pdf&amp;stacc=phs000260.v2.p1
            </para>
      </AcknowledgementText>
      <DocumentSet>
        <DataUseCertificate Label="Data Use Certificate" FilePath="https://dbgap.ncbi.nlm.nih.gov/aa/wga.cgi?page=DUC&amp;view_pdf&amp;stacc=phs000260.v2.p1" FileName="Data_Use_Certification-Foregut_Microbiome_in_Development_of_Esophageal_Adenocarcinoma-Revised_1.26.11.pdf"/>
      </DocumentSet>
    </Policy>
    <ConsentGroups>
      <ParticipantSet groupNum-REF="1">
        <ConsentName>Human Microbiome Research</ConsentName>
        <ConsentAbbrev>HMP</ConsentAbbrev>
        <UseLimitation>These data may be used only for studies related to the human microbiome. Research aimed at understanding the relationships between humans and microbes or identifying the organisms living in or on humans. This includes studies to enumerate the population of the human microbiome, metagenomic studies, functional studies related to the human microbiome, studies that evaluate the impact of the human microbiome on human phenotypes or disease states, studies to develop technologies and analytic tools that can be used in human microbiome research, and studies that will use the data in a way that will contribute to the further understanding of the human microbiome through comparison with non-human data sets. Sequence data generated from microbiome samples will be used only for the purpose of studying
                  the microbial components of the microbiome and will not be used to make inferences about the human host DNA itself.</UseLimitation>
        <IrbRequired>No</IrbRequired>
      </ParticipantSet>
    </ConsentGroups>
  </AuthorizedAccess>
  <Documents>
    <Document phd="phd003534.1" type="questionnaire" createDate="2011-05-03" modDate="2011-05-04" urlToXml="http://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/GetDocumentXml.cgi?document_id=phd003534.1" urlToHtml="http://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/document.cgi?study_id=phs000260.v2.p1&amp;phd=3534">
      <OrigName>Case Report Form.pdf</OrigName>
      <DisplayName>Case Report Form</DisplayName>
      <Description>Case Report Form</Description>
      <displayStatus>public</displayStatus>
      <xmlStatus>public</xmlStatus>
    </Document>
    <Document phd="phd003535.1" type="protocol" createDate="2011-05-03" modDate="2011-05-04" urlToXml="http://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/GetDocumentXml.cgi?document_id=phd003535.1" urlToHtml="http://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/document.cgi?study_id=phs000260.v2.p1&amp;phd=3535">
      <OrigName>Inclusion and Exclusion Criteria 0.docx</OrigName>
      <DisplayName>Old Subject Recruitment Criteria in Esophageal Microbiome study</DisplayName>
      <Description>Old Subject Recruitment Criteria in Esophageal Microbiome study</Description>
      <displayStatus>public</displayStatus>
      <xmlStatus>public</xmlStatus>
    </Document>
    <Document phd="phd003536.1" type="protocol" createDate="2011-05-03" modDate="2011-05-04" urlToXml="http://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/GetDocumentXml.cgi?document_id=phd003536.1" urlToHtml="http://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/document.cgi?study_id=phs000260.v2.p1&amp;phd=3536">
      <OrigName>Inclusion and Exclusion Criteria 1.docx</OrigName>
      <DisplayName>New Subject Recruitment Criteria in Esophageal Microbiome study</DisplayName>
      <Description>New Subject Recruitment Criteria in Esophageal Microbiome study</Description>
      <displayStatus>public</displayStatus>
      <xmlStatus>public</xmlStatus>
    </Document>
    <Document phd="phd003537.1" type="questionnaire" createDate="2011-05-03" modDate="2011-05-04" urlToXml="http://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/GetDocumentXml.cgi?document_id=phd003537.1" urlToHtml="http://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/document.cgi?study_id=phs000260.v2.p1&amp;phd=3537">
      <OrigName>Questionnaire.pdf</OrigName>
      <DisplayName>Study Questionnaire</DisplayName>
      <Description>Study Questionnaire</Description>
      <displayStatus>public</displayStatus>
      <xmlStatus>public</xmlStatus>
    </Document>
  </Documents>

  <Annotations>
    <DocumentPart phd="phd003534.1" sectionId="V10">
      <phvList>
        <phvRef variableId="90630"/>
      </phvList>
    </DocumentPart>
    <DocumentPart phd="phd003534.1" sectionId="V17">
      <phvList>
        <phvRef variableId="90628"/>
      </phvList>
    </DocumentPart>
    <DocumentPart phd="phd003534.1" sectionId="V20a10a">
      <phvList>
        <phvRef variableId="90642"/>
      </phvList>
    </DocumentPart>
    <DocumentPart phd="phd003534.1" sectionId="V20a11a">
      <phvList>
        <phvRef variableId="90637"/>
      </phvList>
    </DocumentPart>
    <DocumentPart phd="phd003534.1" sectionId="V20a12a">
      <phvList>
        <phvRef variableId="90637"/>
      </phvList>
    </DocumentPart>
    <DocumentPart phd="phd003534.1" sectionId="V20a1a">
      <phvList>
        <phvRef variableId="90639"/>
      </phvList>
    </DocumentPart>
    <DocumentPart phd="phd003534.1" sectionId="V20a2a">
      <phvList>
        <phvRef variableId="90640"/>
      </phvList>
    </DocumentPart>
    <DocumentPart phd="phd003534.1" sectionId="V20a3a">
      <phvList>
        <phvRef variableId="90640"/>
      </phvList>
    </DocumentPart>
    <DocumentPart phd="phd003534.1" sectionId="V20a4a">
      <phvList>
        <phvRef variableId="90640"/>
      </phvList>
    </DocumentPart>
    <DocumentPart phd="phd003534.1" sectionId="V20a5a">
      <phvList>
        <phvRef variableId="90640"/>
      </phvList>
    </DocumentPart>
    <DocumentPart phd="phd003534.1" sectionId="V20a6a">
      <phvList>
        <phvRef variableId="90640"/>
      </phvList>
    </DocumentPart>
    <DocumentPart phd="phd003534.1" sectionId="V20a7a">
      <phvList>
        <phvRef variableId="90642"/>
      </phvList>
    </DocumentPart>
    <DocumentPart phd="phd003534.1" sectionId="V20a8a">
      <phvList>
        <phvRef variableId="90642"/>
      </phvList>
    </DocumentPart>
    <DocumentPart phd="phd003534.1" sectionId="V20a9a">
      <phvList>
        <phvRef variableId="90642"/>
      </phvList>
    </DocumentPart>
    <DocumentPart phd="phd003534.1" sectionId="V8sec2b">
      <phvList>
        <phvRef variableId="90628"/>
      </phvList>
    </DocumentPart>
    <DocumentPart phd="phd003535.1" sectionId="phd003535">
      <phvList>
        <phvRef variableId="159408"/>
      </phvList>
    </DocumentPart>
    <DocumentPart phd="phd003536.1" sectionId="phd003536">
      <phvList>
        <phvRef variableId="159408"/>
      </phvList>
    </DocumentPart>
    <DocumentPart phd="phd003537.1" sectionId="V11">
      <phvList>
        <phvRef variableId="90627"/>
      </phvList>
    </DocumentPart>
    <DocumentPart phd="phd003537.1" sectionId="V12">
      <phvList>
        <phvRef variableId="90627"/>
      </phvList>
    </DocumentPart>
    <DocumentPart phd="phd003537.1" sectionId="V13">
      <phvList>
        <phvRef variableId="90627"/>
      </phvList>
    </DocumentPart>
    <DocumentPart phd="phd003537.1" sectionId="V17">
      <phvList>
        <phvRef variableId="90631"/>
      </phvList>
    </DocumentPart>
    <DocumentPart phd="phd003537.1" sectionId="V19">
      <phvList>
        <phvRef variableId="90632"/>
      </phvList>
    </DocumentPart>
    <DocumentPart phd="phd003537.1" sectionId="V2">
      <phvList>
        <phvRef variableId="90620"/>
      </phvList>
    </DocumentPart>
    <DocumentPart phd="phd003537.1" sectionId="V3">
      <phvList>
        <phvRef variableId="90621"/>
      </phvList>
    </DocumentPart>
    <DocumentPart phd="phd003537.1" sectionId="V34a">
      <phvList>
        <phvRef variableId="90635"/>
      </phvList>
    </DocumentPart>
    <DocumentPart phd="phd003537.1" sectionId="V34b">
      <phvList>
        <phvRef variableId="90636"/>
      </phvList>
    </DocumentPart>
    <DocumentPart phd="phd003537.1" sectionId="V3a">
      <phvList>
        <phvRef variableId="90622"/>
      </phvList>
    </DocumentPart>
    <DocumentPart phd="phd003537.1" sectionId="V4">
      <phvList>
        <phvRef variableId="90623"/>
      </phvList>
    </DocumentPart>
    <DocumentPart phd="phd003537.1" sectionId="V42">
      <phvList>
        <phvRef variableId="90633"/>
      </phvList>
    </DocumentPart>
    <DocumentPart phd="phd003537.1" sectionId="V45">
      <phvList>
        <phvRef variableId="90634"/>
      </phvList>
    </DocumentPart>
    <DocumentPart phd="phd003537.1" sectionId="V52a1a">
      <phvList>
        <phvRef variableId="90639"/>
      </phvList>
    </DocumentPart>
    <DocumentPart phd="phd003537.1" sectionId="V52a3a">
      <phvList>
        <phvRef variableId="90641"/>
      </phvList>
    </DocumentPart>
    <DocumentPart phd="phd003537.1" sectionId="V52a4a">
      <phvList>
        <phvRef variableId="90642"/>
      </phvList>
    </DocumentPart>
    <DocumentPart phd="phd003537.1" sectionId="V52a5a">
      <phvList>
        <phvRef variableId="90640"/>
      </phvList>
    </DocumentPart>
    <DocumentPart phd="phd003537.1" sectionId="V52a8a">
      <phvList>
        <phvRef variableId="90638"/>
      </phvList>
    </DocumentPart>
    <DocumentPart phd="phd003537.1" sectionId="V52a9a">
      <phvList>
        <phvRef variableId="90637"/>
      </phvList>
    </DocumentPart>
    <DocumentPart phd="phd003537.1" sectionId="V6">
      <phvList>
        <phvRef variableId="90625"/>
      </phvList>
    </DocumentPart>
    <DocumentPart phd="phd003537.1" sectionId="V6a">
      <phvList>
        <phvRef variableId="90626"/>
      </phvList>
    </DocumentPart>
  </Annotations>



</Study>

</Studies>

</GaPExchange>
